Analyzing the Future of Histone Deacetylase (HDAC) Inhibitors Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the histone deacetylase (hdac) inhibitors market right now?
The market size for histone deacetylase (HDAC) inhibitors has seen robust growth in the recent past. The market is projected to increase from $1.23 billion in 2024 to $1.33 billion in 2025, representing a compound annual growth rate (CAGR) of 7.9%. This significant growth during the historic period can be linked to an increase in funding for research in epigenetics, a surge in incidences of drug-resistant cancers, growing healthcare expenditure, expanded use of HDAC inhibitors in veterinary medicine, and enhanced investment in bioinformatics.
How fast Is the histone deacetylase (hdac) inhibitors market expected to grow, and what’s its future value?
The market size for histone deacetylase (HDAC) inhibitors is predicted to witness substantial expansion in the approaching years, reaching a value of $1.77 billion in 2029, with a compound annual growth rate (CAGR) of 7.5%. The projected increase in the forecast period can be associated with factors such as the escalating prevalence of neurodegenerative illnesses, heightened awareness around cancer, increased investments in drug innovation, a surge in clinical trials, and the growing implementation of personalized healthcare. Dominant trends expected in the forecast period encompass technological evolution, individualized healthcare approaches, synergies of cancer immunotherapy, inclusion of digital healthcare solutions and the use of bioinformatics.
Get your histone deacetylase (hdac) inhibitors market report here!
What are the leading drivers of growth in the histone deacetylase (hdac) inhibitors market?
The increased prevalence of neurodegenerative conditions is projected to fuel the expansion of the histone deacetylase (HDAC) inhibitors market in the future. Neurodegenerative diseases, which are associated with the steady degeneration and death of brain and spinal cord neurons, result in cognitive and motor dysfunction and include illnesses such as Alzheimer’s, characterized by memory loss and cognitive decline due to amyloid plaques and tau tangles. The escalating prevalence of neurodegenerative diseases can be linked to multiple factors, such as age, longevity, genetics, and environmental aspects. Histone deacetylase (HDAC) inhibitors are being considered as potential solutions for neurodegenerative diseases due to their capacity to alter gene expression and provide neuroprotection. For example, in August 2024, the Centers for Disease Control and Prevention, a federal agency based in the United States, stated that an estimated 6.7 million senior citizens in the United States presently suffer from Alzheimer’s disease, a number anticipated to nearly double to 14 million by 2060. Therefore, the growth of the histone deacetylase (HDAC) inhibitors market is being propelled by the escalating prevalence of neurodegenerative diseases.
What are the key segments defining the histone deacetylase (hdac) inhibitors market?
The histone deacetylase (HDAC) inhibitors market covered in this report is segmented –
1) By Class: Class I HDACs, Class II HDACs, Class III HDACs, Class IV HDACs
2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors
3) By Application: Oncology, Neurology, Other Applications
4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users
Subsegments
1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8
2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10
3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7
4) By Class IV HDACs: HDAC11
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp
Who are the key players steering the development of the histone deacetylase (hdac) inhibitors market?
Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.
Which trends are expected to transform the histone deacetylase (hdac) inhibitors market?
Leading corporations in the histone deacetylase (HDAC) inhibitors market are concentrating their efforts on creating unique solutions. These solutions are specifically HDAC inhibitors for the treatment of cancer aimed at improving effectiveness and lowering adverse effects. HDAC inhibitors are a type of pharmaceutical compound utilized in cancer therapy that works by hampering the activity of HDAC enzymes, which typically remove acetyl groups from histone proteins, which leads to increased acetylation of histones and changes to the structure and gene expression of chromatin. For instance, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based company developing pioneering cancer therapies, received new HDAC Inhibitor Patents for Cancer Treatment from the U.S. Patent and Trademark Office. These novel HDAC inhibitors have been specifically designed to target distinct HDAC enzymes tied to cancer progression, with the aim of interfering with the aberrant gene expression patterns promoting tumor growth and metastasis. These patented compounds have proven to have increased potency and selectivity, reducing off-target effects, and thus, improving the safety of patients under treatment.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18386
Which regions are most influential in expanding the histone deacetylase (hdac) inhibitors market?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Interleukin Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report
ACE Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report
Checkpoint Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
